Last reviewed · How we verify
NCT05359315
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
trial testing Interferon-Gamma in Pulmonary Tuberculosis in 84 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | SPP Pharmaclon Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 84 |
| Start date | 15 April 2022 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Interferon-Gamma — full drug profile →
Conditions studied
- Pulmonary Tuberculosis — all drugs for Pulmonary Tuberculosis →
Sponsor
SPP Pharmaclon Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Pulmonary Tuberculosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for intramuscular or subcutaneous administration of 500,000 IU.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05359315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Interferon-Gamma
Trials testing the same drug.
- NCT06118619 — A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis · unknown
- NCT05395702 — Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia · NA · completed
- NCT05065905 — Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis · Phase 1, PHASE2 · completed
Other recruiting trials for Pulmonary Tuberculosis
Currently open trials in the same condition.
- NCT07209761 — A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis · Phase 3 · recruiting
- NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
- NCT07186478 — I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis · NA · active not recruiting
- NCT06649721 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort · Phase 3 · active not recruiting
- NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting
Other SPP Pharmaclon Ltd. trials
Trials by the same sponsor.
- NCT06118619 — A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis · unknown
- NCT05054114 — Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19 · NA · completed
- NCT05386446 — Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19 · completed
- NCT05386459 — Study of the Use of the Drug Ingaron in Patients With COVID-19 · completed
- NCT05395702 — Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05359315 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SPP Pharmaclon Ltd.
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05359315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing